GU medical oncologist @DanaFarber | Believe in a future 🌏 immune to cancer | ❤ & RT ≠ E
Boston, MA
Joined September 2015
- Tweets529
- Following256
- Followers754
- Likes1.1K
Xiao Wei, MD retweeted
Ever wonder if tRNAs can regulate the identity of a cancer cell?
@HsiehLab @FredHutch postdoc @yeonsookim_phd did and discovered a single tRNA that can control lineage dependency and drug sensitivity in prostate cancer published today @Nature: nature.com/articles/s41586-0…
Xiao Wei, MD retweeted
Congrats to Dr. Mary-Ellen Taplin @DanaFarber_GU 👉 “@PCF_News Women in Science Lifetime Achievement Award at #PCFRetreat26! 🎉 a career spent following the questions & putting patients first. A well-deserved standing ovation. 👏 @PCF_Science @urotoday @DrChoueiri @DanaFarber
Xiao Wei, MD retweeted
In today’s plenary session, Mary-Ellen Taplin, MD, shares positive results from the PROTEUS trial showing patients treated with the apalutamide plus hormone therapy regimen were ten times more likely to have little to no cancer present at surgery. #ASCO26
Xiao Wei, MD retweeted
Excited to share our new paper @NatureComms in collaboration with @RickmanLab, led by #RichaSingh @WeillCornell and @Bajji @DanaFarber #BeltranLab
New research published in @NatureComms provides critical mechanistic insights into how prostate cancer becomes resistant to treatment, uncovering how two key epigenetic mechanisms - DNA methylation and EZH2 activity - work together to drive transformation to a more aggressive form of the disease, neuroendocrine prostate cancer. @DanaFarber @bajji @mishabeltran
Read more: bit.ly/4sk61bg
Xiao Wei, MD retweeted
The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26
Xiao Wei, MD retweeted
🗣️Prostate Rapid Oral Abstracts #GU26
👉Dr #JohannDeBono presenting phase 1 #VIR5500 dual masked #PSMA T-cell engager in mCRPC.
n =51 mCRPC (95% post-taxane)
ALL pts >3000ug/kg Q3W
⚠️ G1-2 CRS = 53% 60%
⚠️ >G3 CRS = 2% 7%
ALL pts >3000ug/kg Q3W
🩸PSA 50 = 53% 100%
🩸PSA 90 = 24% 91%
📈 ORR = 18% 67%
🔑Key Data underscoring dose-dependent response rates and low rates of Grade 3 CRS.
@neerajaiims @APCCC_Lugano @PBarataMD @Dr_RaviMadan @xiaoweimd @yekeduz_emre @DrYukselUrun @OncBrothers @OncoAlert @urotoday @Uromigos
Xiao Wei, MD retweeted
Tonight we sit with the cherished memories of a truly unforgettable individual who changed the lives of so many fighting cancer.
Tomorrow we stand and get back to the fight against the terrible disease that took one of our best, brightest, and kindest.
Love you forever, Felix.
Xiao Wei, MD retweeted
We are happy to share our work led by @AramLyu and Zenghua Fan on why prostate cancer is so resistant to immunotherapy.
nature.com/articles/s41586-0…
Xiao Wei, MD retweeted
Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-duration ADT +/- ARPI, met-directed therapy and local therapy (if de novo) for omHSPC, published in @EurUrolOncol:
sciencedirect.com/science/ar…
Xiao Wei, MD retweeted
Honored to be among 12 outstanding oncology leaders on the @ASCO Election ballot! Make your voice heard in shaping our society's future - vote now at asco.org/election. Every ballot strengthens our mission to advance cancer care.
Xiao Wei, MD retweeted
It was such an honor giving the Felix Feng Lecture at the #pcfretreat24 on Friendship and Science. Thank you Felix for all your contributions to the field and for being an amazing friend. The love for you in the room was just palpable @PCF_Science
This Post is from a suspended account. Learn more
Xiao Wei, MD retweeted
We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024
PSMAfore published @TheLancet today. Proud to have contributed to this impactful study. 50-day 🔗 to full-article: authors.elsevier.com/c/1jmkB…
Our poster #ESMO2024 (1646P): ADT + Doce + Nivo in pts with DDR-proficient & immune-cold mHSPC did not meet PSA endpoint; 3/20 pts with durable responses; post-ADT baseline CTCs indicate persistent AR signaling as resistance mechanism. Biomarker ➕ cohorts results to follow. @JoshLangMD @DrRanaMcKay @davidjeinstein @JadChahoud @ChrisSweens1 @ThePCCTC @PCFnews
Xiao Wei, MD retweeted
Huge congrats to @apolo_andrea @sonpavde @DrRosenbergMSK @WilliamKimMD @bergsa83 & the @ALLIANCE_org team on a terrific @myESMO presentation & a concomitant @NEJM paper! A very exciting #ESMO24 indeed!
Xiao Wei, MD retweeted
Terrific overview of BiTEs in #prostatecancer at #ESMO24 by @neerajaiims @huntsmancancer. #PSMA, #STEAP1, #DLL3 & other targets being exploited with varying levels of success. BEAUTIFUL comprehensive tables included in his talk that give immediate perspective of the status of bispecific & trispecifics - @myESMO fellows in attendance - great reference here! @brian_rini @powles_tom @Uromigos
Xiao Wei, MD retweeted
Standing room only for #ESMO24 prostate session, @mishabeltran excellent discussions on DLL3 targeting in neuroendocrine prostate cancer and @neerajaiims on T-cell engagers
Xiao Wei, MD retweeted
Masterful discussion by @VincentWenxinXu of the biomarker data presented, including the KIM-1 data to which he has personally had very important contributions.
@ASCO #ASCO24
Xiao Wei, MD retweeted
What an incredible way to spend last Saturday - surrounded by the brightest minds in the field and more importantly, the brightest lights in my life. Thank you all for coming out and attending the #FengSymposium! I am so grateful for you all 🙏🏼
